Introduction: Yellow Fever vaccine is one of the most successful vaccines ever developed. Nonetheless, restrictions of administration to immunosuppressed and rare adverse events are drawbacks that stimulate the development of safer non-live approaches. As safety increases, however, immunogenicity decreases due to the lack of viral replication. In this context, adjuvants are key elements to activate innate immunity and shape the desired adaptative responses and protection. Adjuvants of different mechanisms of action have been studied and we selected candidates of each class: antigen carriers (Al(OH) 3 and Addavax) and immune potentiators (Flagellin). In this study we intend to identify promising adjuvants for development of an inactivated yellow fever virus (IYFV) vaccine candidate, in preclinical evaluation in mice model.
